Lilly to present Alzheimer’s research at London conference

Eli Lilly will present 16 abstracts at the 2026 Alzheimer’s Association International Conference in London, including new long-term extension and biomarker data for Kisunla (donanemab). The company reported $72.25B in trailing-twelve-month revenue as of Q1 2026, up 47.43%, and it is trading near its 52-week high ($1,249.45) after a 55.6% 1-year run. Multiple analysts raised/maintained bullish targets (e.g., Truist to $1,370; Cantor to $1,350) and expect Lilly to exceed Q2 2026 earnings estimates and potentially raise guidance, while Sandoz’s FDA generic tirzepatide applications add competitive overhang.

Analysis

This conference slate is more about extending confidence in the durability of LLY’s premium than about changing near-term EPS. The real commercial value is not the Alzheimer’s posters themselves; it is whether the safety-management narrative and biomarker data reduce friction for physicians and payers, which can incrementally widen the addressable pool and support a higher multiple for a business already priced for flawless execution.

The second-order implication is diagnostic substitution. If a blood biomarker can reliably triage patients earlier and cheaper than PET, the beneficiary is not just LLY’s drug funnel but also any workflow that moves Alzheimer’s workup out of tertiary centers and into primary care. That is a multi-quarter, possibly multi-year reimbursement story, so investors should not confuse scientific validation with immediate revenue translation.

The bigger risk to the stock is still the obesity franchise math, not this neurology readout. Generic tirzepatide applications are a long-dated overhang that can compress terminal cash flow assumptions well before any actual launch, but the market will likely ignore that until there is regulatory or litigation clarity. Contrarian view: consensus may overstate the conference as a stock catalyst and understate how much the current valuation already discounts good science; any disappointment on safety, persistence, or reimbursement could trigger multiple compression faster than the pipeline can offset it.

Key Decisions for Investors

• Do not chase LLY into the conference; use any 2-4% post-event strength to trim or hedge, because the likely upside is sentiment-driven rather than fundamental.
• On pullbacks, keep LLY on the buy list for a 3-6 month horizon, but size smaller than usual given valuation and the unresolved tirzepatide generic overhang.
• Watch for any update on biomarker reimbursement or guideline adoption; if payers signal coverage momentum over the next 1-3 months, that is the first point to add to LLY and the Alzheimer’s ecosystem names.
• Treat SDZNY as a regulatory watch item, not an immediate short: generic tirzepatide is a 12-24 month thesis unless the FDA clears a faster path than expected.
• If the market gaps LLY up on the abstracts, consider a call spread overwrite or collar rather than outright selling, to keep exposure while reducing downside from valuation compression.